UF Health Cancer Center Seed Grant Opportunities
Bridge Grants Program Now accepting applications
The intent of this grant mechanism is to provide interim support for existing investigator-initiated, cancer-related, research projects that have been highly rated by national panels of peer reviewers in recent federal competitions but were not funded.
Aging has been determined to be an overarching theme that spans across all our cancer programs. The intent of this grant mechanism is to foster collaborations between UF Health Cancer Center (UFHCC) and UF Institute on Aging (IOA) researchers. Such interactions can bring new and exciting directions and focus to an individual’s or a group’s research.
The intent of this grant mechanism is to foster collaborations between the UF Health Cancer Center (UFHCC), UFHCC-Orlando Health (OH), and UF Proton Therapy Institute (UFPTI) cancer researchers. Such interactions can bring new and exciting directions and focus to an individual’s or a group’s research.
The goals of this collaborative team grant program are to:
- Support a broadly based, multi-disciplinary research program with a well-defined major objective or theme
- Create synergies and collaborations between UFHCC, OH, and UFPTI cancer researchers
- Stimulate applications for future program-type federal or national extramural funding
- Address research questions that can only be accomplished through collaborations, networks, and consortia
- Develop strong inter-institutional clinical research collaborations.
The intent of this grant mechanism is to foster new collaborative projects involving the Moffitt Cancer Center, the University of Florida Health Cancer Center and the University of Miami Sylvester Comprehensive Cancer Center. This opportunity is designed to further build collaboration amongst the three centers, each of which is providing funding for the awards. Each proposal requires strong, meaningful collaboration by investigators from at least two of the three centers.
The intent of this grant mechanism is to provide developmental support for promising investigator-initiated, cancer-related, research projects that propose innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, treatment, and control of cancer.
Triple Negative Breast Cancer (TNBC) – defined as estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2) negativity – is heterogeneous with respect to biology, prognosis and response to treatment. TNBC is associated with younger age at diagnosis and with poorer outcomes compared with non-TNBC. Studies to enhance our understanding of TNBC are needed to improve our understanding of its biology and current management and outcome of patients diagnosed with TNBC.